379 related articles for article (PubMed ID: 20028264)
21. A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy.
Fain JM; Kotak S; Mardekian J; Bacharach J; Edward DP; Rauchman S; Brevetti T; Fox JL; Lovelace C
BMC Ophthalmol; 2011 Jun; 11():13. PubMed ID: 21668980
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials.
Aptel F; Cucherat M; Denis P
Eur J Ophthalmol; 2012; 22(1):5-18. PubMed ID: 22167538
[TBL] [Abstract][Full Text] [Related]
23. Efficiency of instillation methods for prostaglandin medications.
Fiscella R; Wilensky JT; Chiang TH; Walt JG
J Ocul Pharmacol Ther; 2006 Dec; 22(6):477-82. PubMed ID: 17238816
[TBL] [Abstract][Full Text] [Related]
24. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
Gagliuso DJ; Wang RF; Mittag TW; Podos SM
Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study.
Kammer JA; Katzman B; Ackerman SL; Hollander DA
Br J Ophthalmol; 2010 Jan; 94(1):74-9. PubMed ID: 19726422
[TBL] [Abstract][Full Text] [Related]
26. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.
Eisenberg DL; Toris CB; Camras CB
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S105-15. PubMed ID: 12204706
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Kymes S
Am J Ophthalmol; 2006 Aug; 142(2):354; author reply 354-5. PubMed ID: 16876536
[No Abstract] [Full Text] [Related]
28. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness.
Zhong Y; Shen X; Yu J; Tan H; Cheng Y
Cornea; 2011 Aug; 30(8):861-4. PubMed ID: 21499083
[TBL] [Abstract][Full Text] [Related]
29. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost.
Stewart WC; Kolker AE; Stewart JA; Leech J; Jackson AL
Am J Ophthalmol; 2003 Mar; 135(3):314-20. PubMed ID: 12614748
[TBL] [Abstract][Full Text] [Related]
30. Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe.
Stewart WC; Stewart JA; Nelson LA; Kruft B
Eur J Ophthalmol; 2008; 18(2):199-204. PubMed ID: 18320511
[TBL] [Abstract][Full Text] [Related]
31. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.
Kucukevcilioglu M; Bayer A; Uysal Y; Altinsoy HI
Clin Exp Ophthalmol; 2014 Mar; 42(2):126-31. PubMed ID: 23844550
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK general practitioner research database.
De Natale R; Lafuma A; Berdeaux G
Clin Drug Investig; 2009; 29(2):111-20. PubMed ID: 19133706
[TBL] [Abstract][Full Text] [Related]
33. [Monotherapy with lipid structural derivatives in glaucoma].
Călugăru D; Călugăru M
Oftalmologia; 2010; 54(2):30-43. PubMed ID: 20827909
[TBL] [Abstract][Full Text] [Related]
34. Incidence of hyperemia associated with bimatoprost treatment in naïve subjects and in subjects previously treated with latanoprost.
Kurtz S; Mann O
Eur J Ophthalmol; 2009; 19(3):400-3. PubMed ID: 19396785
[TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma.
Sato S; Hirooka K; Baba T; Mizote M; Fujimura T; Tenkumo K; Ueda H; Shiraga F
J Ocul Pharmacol Ther; 2011 Oct; 27(5):499-502. PubMed ID: 21790301
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension.
Heo JH; Rascati KL; Wilson JP; Lawson KA; Richards KM; Nair R
J Manag Care Spec Pharm; 2019 Sep; 25(9):1001-1010. PubMed ID: 31456491
[TBL] [Abstract][Full Text] [Related]
38. [Cost-efficacy analysis of fixed combinations of prostaglandin/prostamide for treating glaucoma].
Martínez A; Slof J
Arch Soc Esp Oftalmol; 2008 Oct; 83(10):595-600. PubMed ID: 18855279
[TBL] [Abstract][Full Text] [Related]
39. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension.
Fiscella R; Walt J
Drugs Aging; 2006; 23(1):39-47. PubMed ID: 16492068
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.
Aptel F; Cucherat M; Denis P
J Glaucoma; 2008 Dec; 17(8):667-73. PubMed ID: 19092464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
